The U.S. Justice Department (DOJ) has slammed a second drug manufacturer’s motion before a federal court to block implementation of the 340B program’s new administrative dispute resolution (ADR) process.
First, on Feb. 16 in a federal district court in Indiana, DOJ forcefully opposed Eli Lilly’s motion for an injunction against the ADR process. Then, nine days later, in federal district court in New Jersey, DOJ likewise forcefully opposed Sanofi’s Feb. 2 motion challenging the 340B ADR rule.
The U.S. Justice Department (DOJ) has slammed a second drug manufacturer’s motion before a federal court to block implementation of the 340B program’s new administrative dispute resolution (ADR) process.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
